Katie Heller

February 25, 2021
Dr. O'Dwyer and Dr. Schnall

From the Co-Chairs, February 2021

COVID-19 vaccination and patients with cancer; the impact of delayed screening; a virtual Spring 2021 Group Meeting
February 25, 2021
Older patient throat exam

Now Enrolling: EA3191 for Head and Neck Squamous Cell Carcinoma

This three-arm phase II study, led by Dr. Dan Zandberg, is evaluating pembrolizumab immunotherapy after surgery in patients with recurrent or second primary head and neck cancer with high-risk features
February 25, 2021
Patient and doctor talking in office

Trial Spotlight: Shaji Kumar on the EQUATE Study for Newly Diagnosed Multiple Myeloma

The randomized EAA181 phase III trial seeks to determine whether there is any survival benefit from adding a fourth drug to induction therapy—and if so, in which patients
February 25, 2021
NYU Perlmutter Cancer Center

Institution Spotlight: Laura and Isaac Perlmutter Cancer Center at NYU Langone Health

A Standing Main Member of ECOG-ACRIN since 2007
February 25, 2021
News in Brief

News in Brief, February 2021

January 25, 2021
Dr. O'Dwyer and Dr. Schnall

From the Co-Chairs, January 2021

The co-chairs look ahead to the new year, and acknowledge key successes from 2020—despite its many challenges
January 25, 2021
Doctor with male patient

Now Enrolling: EA8183 / ERADICATE for Patients with Localized Prostate Cancer

This phase III study, led by Dr. Alicia Morgans, is exploring a new treatment option for patients with prostate cancer with high-risk features
January 25, 2021
Woman patient speaking with doctor

Now Enrolling: EA2197 / OPT-IN for Gallbladder Cancer

This phase II/III study, led by Dr. Shishir Maithel, is assessing the role of neoadjuvant therapy for patients with incidental gallbladder cancer
January 25, 2021
Pink Rubik's cube

Joe Sparano: Refining Individual Risk in Breast Cancer

Dr. Sparano discusses the scientific and statistical collaboration behind a new tool, RSClin™, which integrates clinical–pathological and genomic risk information to guide adjuvant chemotherapy in node-negative breast cancer
January 25, 2021
PrECOG logo

Trial Spotlight: Jonathan Cohen, MD on Trial PrE0404 for Relapsed/Refractory Mantle Cell Lymphoma

This phase I/II study, led by Dr. Jonathon Cohen, is evaluating the combination of ibrutinib and the oral proteasome inhibitor ixazomib in patients with relapsed/refractory mantle cell lymphoma
January 25, 2021
News in Brief

News in Brief, January 2021